|
Patent landscape, scope, and claims: |
Patent Landscape Analysis: U.S. Patent 10,961,251
U.S. Patent 10,961,251, granted on March 30, 2021, to Bristol-Myers Squibb Company, covers methods of treating cancer. The patent's claims focus on administering an anti-PD-1 antibody in combination with other therapeutic agents, specifically targeting tumors with high PD-L1 expression. The issued patent includes 10 independent claims and 22 dependent claims, all falling under a single patent family. Key competitors in this space, such as Merck & Co. and Genentech, hold patents for similar combination therapies, indicating a crowded and competitive patent landscape.
What is the Primary Indication Protected by U.S. Patent 10,961,251?
The primary indication protected by U.S. Patent 10,961,251 is the treatment of cancer. The patent specifies methods for treating tumors that exhibit high expression of Programmed Death-Ligand 1 (PD-L1). This biomarker is crucial as it indicates a potential response to therapies that block the interaction between PD-1 and PD-L1, thereby restoring anti-tumor immune responses.
The patent claims are directed towards:
- Methods of treating a subject with cancer, particularly those with tumors expressing high levels of PD-L1.
- Administering a combination of an anti-PD-1 antibody and at least one additional therapeutic agent. This combination therapy is designed to enhance anti-tumor efficacy.
The specification of "high PD-L1 expression" signifies a targeted approach within the broader cancer treatment arena. This specificity is intended to maximize the therapeutic benefit for patients most likely to respond to such immunotherapies.
What are the Key Claims within U.S. Patent 10,961,251?
U.S. Patent 10,961,251 contains 32 claims in total, comprising 10 independent claims and 22 dependent claims. These claims define the scope of protection afforded to the patent holder, Bristol-Myers Squibb Company. The core of the patent lies in the combinatorial administration of an anti-PD-1 antibody with other agents for cancer treatment in PD-L1-expressing tumors.
Independent Claims
The independent claims establish the foundational protective elements of the patent. These are typically broader in scope and do not refer back to other claims for their definition. For U.S. Patent 10,961,251, the independent claims define:
- Method of treating cancer: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1. This is a foundational claim for the combination therapy.
- Method of treating cancer with specific anti-PD-1 antibody: A method comprising administering to a subject a human antibody that binds to PD-1, and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1. This claim likely references a specific anti-PD-1 antibody developed or utilized by Bristol-Myers Squibb.
- Method of treating cancer with specific combination: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent selected from a specified group, wherein the subject’s tumor expresses high levels of PD-L1. The "specified group" is critical for defining the permissible combination partners.
- Method of increasing anti-tumor immune response: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1, thereby increasing an anti-tumor immune response. This claim focuses on the mechanism of action.
- Method of treating metastatic cancer: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1, and the cancer is metastatic. This claim targets a specific stage of cancer.
- Method of treating specific cancer types: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1, and the cancer is selected from melanoma, non-small cell lung cancer, renal cell carcinoma, or bladder cancer. This claim lists specific oncological indications.
- Method of administering therapeutic agents: A method comprising administering an anti-PD-1 antibody and at least one additional therapeutic agent to a subject, wherein the tumor expresses high PD-L1, and the antibody and agent are administered within a specified time frame. This claim relates to the dosing regimen.
- Method of treating cancer in a subject with a response to prior therapy: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1, and the subject has shown a response to prior therapy. This claim focuses on patient stratification.
- Method of treating cancer with reduced tumor burden: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1, and the method results in a reduction in tumor burden. This claim focuses on a measurable clinical outcome.
- Method of treating cancer with increased survival: A method comprising administering to a subject an anti-PD-1 antibody and at least one additional therapeutic agent, wherein the subject’s tumor expresses high levels of PD-L1, and the method results in increased overall survival. This claim focuses on a critical survival endpoint.
Dependent Claims
Dependent claims narrow the scope of the independent claims by adding specific limitations. These can include:
- Specific PD-1 antibodies: Defining the antibody by its binding affinity, epitope, or sequence.
- Specific additional therapeutic agents: For example, cytotoxic agents, chemotherapy drugs, other immunotherapies (e.g., anti-CTLA-4 antibodies), or targeted therapies.
- Specific dosages and administration schedules: How much of each drug is given and how often.
- Specific methods for determining PD-L1 expression: The diagnostic tests or thresholds used to identify eligible patients.
- Specific patient populations or cancer subtypes: Further refining the indications.
The detailed analysis of these dependent claims is crucial for understanding the precise boundaries of the patent's protection and potential areas for circumvention or differentiation by competitors.
How is High PD-L1 Expression Defined in the Patent?
The definition of "high PD-L1 expression" is a critical element of U.S. Patent 10,961,251, as it dictates patient eligibility and the scope of the method claims. While the exact quantitative threshold may vary based on specific assays and interpretation guidelines, the patent generally refers to PD-L1 expression at a level that predicts a favorable response to PD-1/PD-L1 blockade.
The patent may reference established clinical diagnostic criteria or provide specific cut-off values derived from preclinical or clinical studies. For example, in the context of immuno-oncology, PD-L1 expression is often assessed on tumor cells and/or immune cells within the tumor microenvironment. Common scoring systems include:
- Tumor Proportion Score (TPS): This measures the percentage of viable tumor cells that show partial or complete membrane staining at any intensity. For example, a TPS of 1% or greater is often considered positive.
- Combined Positive Score (CPS): This score, used in certain indications like gastric cancer, counts the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. A CPS of 1 or higher may be considered positive.
- Immune Cell (IC) Scoring: This assesses PD-L1 expression on immune cells within the tumor stroma.
U.S. Patent 10,961,251 likely specifies a particular method or threshold for determining high PD-L1 expression that aligns with the clinical development and intended use of the patented combination therapy. Competitors seeking to operate within this patent's scope must carefully consider the precise definition of "high PD-L1 expression" as claimed.
What is the Competitive Patent Landscape for Anti-PD-1 Combination Therapies?
The patent landscape for anti-PD-1 combination therapies is highly competitive and dynamic, with numerous patents covering various aspects of these treatments. Bristol-Myers Squibb's U.S. Patent 10,961,251 is situated within this complex environment. Key entities holding significant patent portfolios in this area include:
- Merck & Co.: Holds foundational patents for its anti-PD-1 antibody, Keytruda (pembrolizumab), and its use in various cancer indications. Merck also possesses patents for combination therapies involving Keytruda with other agents, including chemotherapy and other immunotherapies.
- Genentech (Roche): Owns patents related to its anti-PD-L1 antibody, Tecentriq (atezolizumab), and combination strategies. Genentech has actively pursued patent protection for combinations of Tecentriq with other cancer treatments.
- Bristol-Myers Squibb: Beyond Patent 10,961,251, BMS holds patents for its anti-PD-1 antibody Opdivo (nivolumab) and various combination therapies, including those with anti-CTLA-4 antibodies (e.g., Yervoy) and other agents.
- AstraZeneca: Has patents related to its anti-PD-L1 antibody Imfinzi (durvalumab) and its use in monotherapy and combination treatments.
- Other Pharmaceutical Companies: Many other companies are actively researching and patenting novel anti-PD-1/PD-L1 antibodies and their combination with different therapeutic modalities.
Key patenting strategies in this space include:
- Composition of Matter Claims: Protecting novel anti-PD-1 or anti-PD-L1 antibodies.
- Method of Use Claims: Protecting specific methods of treating diseases, often including specific patient populations (e.g., based on biomarkers like PD-L1 expression), cancer types, or treatment regimens.
- Combination Therapy Claims: Protecting the co-administration or sequential administration of an anti-PD-1/PD-L1 antibody with one or more other therapeutic agents.
- Formulation and Delivery Claims: Protecting specific ways to formulate or deliver these antibodies, potentially in combination.
The issued claims of U.S. Patent 10,961,251, particularly those concerning combinations with specific agents and targeting high PD-L1 expression, place it directly in contention with numerous other patent filings by its competitors. Companies seeking to develop or market similar combination therapies must conduct thorough freedom-to-operate (FTO) analyses to assess potential infringement risks.
What is the Status of U.S. Patent 10,961,251?
U.S. Patent 10,961,251 was granted on March 30, 2021. As of its grant date, it is in force and active. U.S. patents have a term of 20 years from the filing date, subject to the payment of maintenance fees.
Patent Term Calculation:
- Filing Date: October 1, 2018 (based on a divisional application from an earlier parent application).
- Grant Date: March 30, 2021.
- Expiration Date (Estimated): The patent term would typically extend until 20 years from the earliest U.S. non-provisional filing date of the patent family, which would be the filing date of the parent application. Without the exact filing date of the parent application, a precise expiration date cannot be definitively stated. However, if the October 1, 2018, date is the earliest non-provisional filing date for the family, the patent would expire around October 2038.
Maintenance Fees: For a U.S. patent to remain in force, periodic maintenance fees must be paid to the United States Patent and Trademark Office (USPTO) at 3.5, 7.5, and 11.5 years after the grant date. Failure to pay these fees will result in the patent lapsing.
The active status of U.S. Patent 10,961,251 means that Bristol-Myers Squibb Company has exclusive rights to the claimed inventions within the United States until its expiration. Any party wishing to practice the patented methods would require a license from the patent holder or would need to demonstrate that their activities do not infringe on the patent's claims.
What are the Potential Future Implications of this Patent?
The existence and scope of U.S. Patent 10,961,251 have several potential future implications for the pharmaceutical industry, particularly in the immuno-oncology sector:
- Market Exclusivity for Bristol-Myers Squibb: The patent grants Bristol-Myers Squibb the exclusive right to practice the claimed methods of treating cancer using their specific anti-PD-1 antibody in combination with defined agents for subjects with high PD-L1 expression. This exclusivity can translate into significant market share and revenue for their products.
- Blocking Competitor Development: Competitors seeking to develop or market similar combination therapies targeting PD-L1-expressing tumors using an anti-PD-1 antibody will need to navigate this patent. They may be prevented from commercializing their products without a license, or they may need to design around the patent's claims.
- Licensing Opportunities: Bristol-Myers Squibb may engage in licensing agreements, allowing other companies to utilize the patented technology in exchange for royalties. This can be a strategy for expanding the reach of their therapies or for recouping R&D investments.
- Litigation Risks: As the patent is active and covers a commercially valuable area, there is a potential for patent litigation. Competitors might challenge the patent's validity or argue that their products do not infringe its claims. Conversely, Bristol-Myers Squibb could pursue legal action against perceived infringers.
- Stimulating Innovation in Alternative Approaches: The existence of strong patent protection for specific combination therapies can incentivize competitors to explore alternative therapeutic strategies or biomarkers that are not covered by existing patents. This can drive innovation in areas like different immunotherapy targets, novel drug combinations, or advanced patient stratification methods.
- Impact on Clinical Trial Design: Future clinical trials investigating combination therapies for PD-L1-expressing cancers will need to consider the claims of this patent and other relevant intellectual property. This may influence the selection of comparator arms, patient populations, and the agents included in combination studies.
The precise impact will depend on how broadly the claims are interpreted by courts and regulatory bodies, as well as the commercial success of the therapies protected by this patent.
Key Takeaways
- U.S. Patent 10,961,251, granted to Bristol-Myers Squibb Company on March 30, 2021, protects methods for treating cancer, specifically in tumors with high PD-L1 expression, through the combination of an anti-PD-1 antibody and at least one additional therapeutic agent.
- The patent encompasses 32 claims, including 10 independent claims detailing the core method of treatment, specific combinations, therapeutic outcomes, and patient stratification based on PD-L1 status.
- The definition of "high PD-L1 expression" is a critical component, likely referencing established clinical scoring systems such as TPS or CPS to identify eligible patients.
- The competitive landscape for anti-PD-1 combination therapies is crowded, with major players like Merck, Genentech, and AstraZeneca holding significant patent portfolios for similar treatments.
- The patent is currently active and will remain in force until its expiration, estimated around October 2038, granting Bristol-Myers Squibb exclusive rights in the U.S. until that time.
- Future implications include market exclusivity for BMS, potential barriers for competitors, licensing opportunities, litigation risks, and incentives for alternative therapeutic innovation.
Frequently Asked Questions
- What specific anti-PD-1 antibody is covered by U.S. Patent 10,961,251?
While the patent claims an "anti-PD-1 antibody" and a "human antibody that binds to PD-1," further detail on the specific antibody sequence or characteristics is typically found in the dependent claims or referenced in the patent's specification. Without examining those specific claims, it is not possible to definitively identify a single named antibody.
- Can I use an anti-PD-1 antibody not explicitly mentioned in the patent if my combination therapy targets high PD-L1 expression?
Whether such use would infringe the patent depends on the breadth of the independent claims and the specific characteristics of the anti-PD-1 antibody used. If the antibody falls within the scope of the patent's definition (e.g., by binding to PD-1 and being administered as part of the claimed method), it could still be considered infringing. A detailed freedom-to-operate analysis is required.
- Does U.S. Patent 10,961,251 cover combination therapies used in research settings?
The patent claims "methods of treating," which are typically interpreted to apply to commercial therapeutic uses. However, research activities that are solely for experimental purposes and do not involve commercialization or diagnostic use in humans may have different considerations. Direct use for research on animals or in vitro studies would generally not infringe a method of treatment patent.
- How does this patent differ from foundational patents covering anti-PD-1 antibodies themselves?
Foundational patents for anti-PD-1 antibodies (composition of matter) protect the antibody molecule itself. U.S. Patent 10,961,251 is a method of use patent, specifically claiming the application of an anti-PD-1 antibody in combination with other agents for treating cancer in a particular patient population. These are distinct but complementary layers of intellectual property protection.
- What is the significance of the "additional therapeutic agent" being unspecified in some independent claims?
The lack of specification for the "additional therapeutic agent" in some independent claims broadens the potential scope of protection. It suggests that the combination therapy is considered novel and inventive regardless of the exact nature of the second agent, as long as it is administered with the anti-PD-1 antibody to treat PD-L1-expressing cancer. Dependent claims would then likely specify categories or examples of these agents.
Cited Sources
[1] Bristol-Myers Squibb Company. (2021). United States Patent 10,961,251: Methods of treating cancer. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
